SCHEMBL5364381

SCHEMBL5364381

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(I)c(OCc3ccccc3)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.45
EGFR P00533 3/20 0.45
IGF1R P08069 1/20 0.43
SRC P12931 7/20 0.43
KDR P35968 5/20 0.42
CDK2 P24941 2/20 0.42
NTRK1 P04629 1/20 0.41
FCER2 P06734 1/20 0.41
SYK P43405 1/20 0.41
NTRK3 Q16288 1/20 0.41
NTRK2 Q16620 1/20 0.41
AURKA O14965 1/20 0.40
LCK P06239 4/20 0.39
FYN P06241 4/20 0.39
YES1 P07947 4/20 0.39
FGFR1 P11362 4/20 0.39
PDGFRB P09619 3/20 0.39
PRKDC P78527 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361957 0.94 ERBB2 (0.48) ERBB2EGFRIGF1RSRCKDR
SCHEMBL5369490 0.90 ERBB2 (0.47) ERBB2EGFRIGF1RSRCKDR
SCHEMBL5362797 0.90 ERBB2 (0.56) ERBB2EGFRIGF1RSRCKDR
SCHEMBL5376628 0.87 AR (0.47) ERBB2EGFRIGF1RPRKDC
SCHEMBL5358204 0.87 ERBB2 (0.55) ERBB2EGFRIGF1RSRCKDR
SCHEMBL5366175 0.86 ERBB2 (0.51) ERBB2EGFRIGF1RNTRK1MAOA
SCHEMBL5363020 0.86 ERBB2 (0.54) ERBB2EGFRIGF1RSRCKDR
SCHEMBL5368362 0.84 SRC (0.49) SRCKDRCDK2NTRK1FCER2
SCHEMBL5358813 0.82 ERBB2 (0.47) ERBB2EGFRIGF1RMAOAMAOB
SCHEMBL5368923 0.82 ERBB2 (0.59) ERBB2EGFRIGF1RSRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885IGF1R 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.